Shares of The Chemours Company (NYSE:CC – Get Free Report) have been assigned an average recommendation of “Hold” from the eight research firms that are presently covering the company, Marketbeat reports. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $25.38.
A number of brokerages recently weighed in on CC. BMO Capital Markets boosted their price target on shares of Chemours from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, October 7th. Barclays dropped their target price on shares of Chemours from $22.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Wednesday, September 25th. JPMorgan Chase & Co. decreased their price target on shares of Chemours from $25.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, August 6th. UBS Group dropped their price objective on Chemours from $30.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Finally, Royal Bank of Canada decreased their target price on Chemours from $35.00 to $28.00 and set an “outperform” rating for the company in a research report on Friday, October 11th.
Get Our Latest Stock Analysis on Chemours
Hedge Funds Weigh In On Chemours
Chemours Price Performance
Chemours stock opened at $18.89 on Tuesday. The stock has a market cap of $2.81 billion, a P/E ratio of -8.76 and a beta of 1.74. The company has a quick ratio of 1.01, a current ratio of 1.89 and a debt-to-equity ratio of 5.45. The company’s 50 day moving average price is $18.97 and its two-hundred day moving average price is $22.83. Chemours has a 52 week low of $15.10 and a 52 week high of $32.70.
Chemours (NYSE:CC – Get Free Report) last issued its quarterly earnings results on Thursday, August 1st. The specialty chemicals company reported $0.38 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.19). The business had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.53 billion. Chemours had a return on equity of 33.21% and a net margin of 2.16%. The business’s revenue was down 6.4% compared to the same quarter last year. During the same quarter last year, the business posted $1.10 earnings per share. On average, equities analysts predict that Chemours will post 1.32 earnings per share for the current year.
Chemours Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, September 13th. Shareholders of record on Thursday, August 15th were given a dividend of $0.25 per share. The ex-dividend date was Thursday, August 15th. This represents a $1.00 annualized dividend and a dividend yield of 5.29%. Chemours’s dividend payout ratio is currently -46.08%.
Chemours Company Profile
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
Read More
- Five stocks we like better than Chemours
- There Are Different Types of Stock To Invest In
- Analysts Predict New Highs for Cybersecurity Stock by Christmas
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Nuclear Power Reaches Critical Mass: Top Stocks to Watch Now
- Quiet Period Expirations Explained
- 2 Energy Stocks Surging on Billion-Dollar DOE Loan Commitments
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.